Lumosa Therapeutics Future Growth
Future criteria checks 2/6
Lumosa Therapeutics is forecast to grow earnings and revenue by 20.2% and 30.8% per annum respectively while EPS is expected to grow by 21.2% per annum.
Key information
20.2%
Earnings growth rate
21.2%
EPS growth rate
| Pharmaceuticals earnings growth | 59.6% |
| Revenue growth rate | 30.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 08 Oct 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 62 | -308 | N/A | -349 | 1 |
| 12/31/2024 | 59 | -437 | -471 | -464 | 2 |
| 9/30/2024 | 38 | -389 | -273 | -270 | N/A |
| 6/30/2024 | 48 | -281 | -297 | -284 | N/A |
| 3/31/2024 | 53 | -499 | -346 | -331 | N/A |
| 12/31/2023 | 57 | -238 | -343 | -328 | N/A |
| 9/30/2023 | 53 | -86 | -306 | -293 | N/A |
| 6/30/2023 | 41 | -121 | -329 | -327 | N/A |
| 3/31/2023 | 32 | -165 | -306 | -303 | N/A |
| 12/31/2022 | 27 | -495 | -303 | -300 | N/A |
| 9/30/2022 | 22 | -862 | -439 | -437 | N/A |
| 6/30/2022 | 18 | -239 | -422 | -420 | N/A |
| 3/31/2022 | 18 | -156 | -437 | -436 | N/A |
| 12/31/2021 | 17 | 96 | -453 | -453 | N/A |
| 9/30/2021 | 21 | 339 | -360 | -359 | N/A |
| 6/30/2021 | 22 | -177 | -379 | -379 | N/A |
| 3/31/2021 | 22 | -144 | -368 | -367 | N/A |
| 12/31/2020 | 22 | -323 | -130 | -129 | N/A |
| 9/30/2020 | 168 | -333 | -269 | -268 | N/A |
| 6/30/2020 | 169 | -364 | -238 | -238 | N/A |
| 3/31/2020 | 167 | -272 | -180 | -196 | N/A |
| 12/31/2019 | 172 | -241 | -363 | -380 | N/A |
| 9/30/2019 | 30 | -134 | -138 | -150 | N/A |
| 6/30/2019 | 61 | -68 | -96 | -108 | N/A |
| 3/31/2019 | 59 | -114 | -85 | -80 | N/A |
| 12/31/2018 | 61 | -50 | -87 | -82 | N/A |
| 9/30/2018 | 45 | -109 | -99 | -98 | N/A |
| 6/30/2018 | 15 | -146 | N/A | -95 | N/A |
| 3/31/2018 | 19 | -183 | N/A | -76 | N/A |
| 12/31/2017 | 35 | -213 | N/A | -68 | N/A |
| 9/30/2017 | 32 | -225 | N/A | -116 | N/A |
| 6/30/2017 | 30 | -248 | N/A | -95 | N/A |
| 3/31/2017 | 38 | -223 | N/A | -136 | N/A |
| 12/31/2016 | 12 | -230 | N/A | -143 | N/A |
| 9/30/2016 | 22 | -204 | N/A | -98 | N/A |
| 6/30/2016 | 22 | -231 | N/A | -148 | N/A |
| 3/31/2016 | 10 | -247 | N/A | -141 | N/A |
| 12/31/2015 | 10 | -235 | N/A | -138 | N/A |
| 9/30/2015 | N/A | -271 | N/A | -155 | N/A |
| 6/30/2015 | N/A | -239 | N/A | -126 | N/A |
| 3/31/2015 | N/A | -189 | N/A | -99 | N/A |
| 12/31/2014 | N/A | -157 | N/A | -76 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6535 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6535 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6535 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6535's revenue (30.8% per year) is forecast to grow faster than the TW market (12.6% per year).
High Growth Revenue: 6535's revenue (30.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 6535's Return on Equity is forecast to be high in 3 years time